These findings parallel those of Shaikh et al. (7), who observed CSF/plasma ratios of trough drug concentrations of 17 (2.39/0.14 g/ml) and 1.9 (2.98/1.53 g/ml) after 2 and 19 days, respectively, in one patient affected with vancomycin-resistantenterococcus meningitis, successfully treated with 600 mg of intravenous linezolid.
Also, the relatively constant CSF linezolid concentration observed at the end of 1-h drug infusion confirms a slow flow of linezolid across the blood-brain barrier, as suggested by Shaikh (7) .
As a matter of fact, CSF linezolid peak concentrations are relatively delayed, and the CSF/plasma trough ratios obtained in our study and in Shaikh et al.'s are higher than those in patients without meningitis (6) . Such findings, which are in agreement with linezolid's amphiphilic properties (log partition coefficient between n-octanol and water, 0.55), indicate that the severity of meningeal inflammation could influence penetration of linezolid into the brain and the CSF.
Even though a complete pharmacokinetic profile of linezolid in CSF could not be obtained, our results show that the daily dose of 600 mg produces plasma and CFS linezolid concentrations greater than those predicted to be effective against a variety of clinically important multidrug-resistant cocci (6). 
